Burge P S, Efthimiou J, Turner-Warwick M, Nelmes P T
Clin Allergy. 1982 Nov;12(6):523-31. doi: 10.1111/j.1365-2222.1982.tb02551.x.
The blocking effects of inhaled beclomethasone dipropionate (BDP) and fluocortin butyl ester (FCB) on the immediate and late asthmatic reactions induced by inhaled allergen were studied in two trials. In the first, a double-blind cross-over trial compared BDP (800 micrograms daily as powder) with FCB 8 mg daily (1:20 by wt.-Formulation 1). The second trial was identical in design and compared FCB 8 mg daily (1:20) with FCB 8 mg daily as Formulation 2 (1:40). Known BDP, 400 micrograms daily by pressurized aerosol was studied at the end of the second trial. Allergen provocation was performed before and after 7 days treatment with each drug, with a 2-week interval between each drug. Overall, a blocking index for the immediate reaction of greater than 50% was obtained in ten of twenty patients (50%) using BDP, and five of twenty-one (25%) using FCB (P less than 0.01). The late reaction was blocked in nine of eleven (82%) instances on BDP, and four of fourteen (33%) on FCB. Contrary to earlier reports, inhaled corticosteroid agents used for several days prior to bronchial challenge, were found to block both the immediate as well as the late reaction in many individuals.
在两项试验中研究了吸入丙酸倍氯米松(BDP)和丁地去炎松(FCB)对吸入变应原诱发的速发和迟发哮喘反应的阻断作用。在第一项试验中,一项双盲交叉试验将BDP(每日800微克,粉剂)与每日8毫克FCB(重量比1:20,制剂1)进行比较。第二项试验设计相同,将每日8毫克FCB(1:20)与每日8毫克FCB制剂2(1:40)进行比较。在第二项试验结束时研究了已知的每日400微克BDP(通过压力气雾剂)。在每种药物治疗7天之前和之后进行变应原激发试验,每种药物之间间隔2周。总体而言,使用BDP的20名患者中有10名(50%)速发反应阻断指数大于50%,使用FCB的21名患者中有5名(25%)(P<0.01)。BDP组11例中有9例(82%)迟发反应被阻断,FCB组14例中有4例(33%)。与早期报告相反,发现在支气管激发试验前使用几天的吸入性皮质类固醇药物在许多个体中可阻断速发和迟发反应。